COPY | Jotup

MRCY Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed against Mercury Systems, Inc. (MRCY)

Retrieved on:

Friday, February 2, 2024

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been against Mercury Systems, Inc. (“Mercury”) ( NASDAQ: MRCY ).

Key Points:

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been against Mercury Systems, Inc. (“Mercury”) ( NASDAQ: MRCY ).
The action charges Mercury with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
Kessler Topaz Meltzer & Check, LLP encourages Mercury investors who have suffered significant losses to contact the firm directly to acquire more information.
The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

MDRX Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Veradigm Inc. (MDRX) of Deadline in Securities Fraud Class Action Lawsuit

Retrieved on:

Thursday, January 18, 2024

LLP, Accounting, CFO, Insurance, Class, District court, Court, COPY, Annual report, Nature, News, Lead, Pharmaceutical industry

The action charges Veradigm with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.

Key Points:

The action charges Veradigm with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.
As a result of Veradigm's materially misleading statements and omissions to the public, Veradigm's investors have suffered significant losses.
During the Class Period, defendants emphasized Veradigm's strong revenue, gross margin, and EBITDA growth to investors during the company's quarterly earnings calls.
Kessler Topaz Meltzer & Check, LLP encourages Veradigm investors who have suffered significant losses to contact the firm directly to acquire more information.

MRCY ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Mercury Systems, Inc. (MRCY) Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

Retrieved on:

Sunday, January 28, 2024

MRCY, LLP, Mercury, Person, Medicare, Mercury Systems, CFTC, Fraud, District court, Court, COPY, Acquisition, IRS, Glass house, Research, News, Lead

The action charges Mercury with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points:

The action charges Mercury with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
As a result of Mercury’s materially misleading statements and omissions to the public, Mercury’s investors have suffered significant losses.
Our securities fraud litigators are regularly recognized as leaders in the field as well as the firm itself which is continuously awarded for the successful results we’ve achieved.
Kessler Topaz Meltzer & Check, LLP encourages Mercury investors who have suffered significant losses to contact the firm directly to acquire more information.

BNTX CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against BioNTech SE (BNTX)

Retrieved on:

Saturday, January 27, 2024

RADNOR, Pa., Jan. 27, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).

Key Points:

RADNOR, Pa., Jan. 27, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).
The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
As a result of BioNTech’ s materially misleading statements and omissions to the public, BioNTech’ s investors have suffered significant losses.
Kessler Topaz Meltzer & Check, LLP encourages BioNTech investors who have suffered significant losses to contact the firm directly to acquire more information.

Kessler Topaz Meltzer & Check, LLP Reminds Cummins Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

Retrieved on:

Saturday, January 27, 2024

CMI, LLP, EPA, Person, Medicare, RAM, CFTC, DOJ, Fraud, District court, COPY, Court, IRS, News, Lead, Certification, Pharmaceutical industry

The action charges Cummins with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points:

The action charges Cummins with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
As a result of Cummins’ s materially misleading statements and omissions to the public, Cummins’ s investors have suffered significant losses.
Kessler Topaz Meltzer & Check, LLP encourages Cummins investors who have suffered significant losses to contact the firm directly to acquire more information.
The class action complaint against Cummins, Baker v. Cummins Inc., et al., Case No.

Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for ChargePoint Holdings, Inc. Investors in Securities Fraud Class Action Lawsuit

Retrieved on:

Thursday, January 25, 2024

LLP, Person, CFO, Medicare, CFTC, Fraud, District court, COPY, GAAP, Court, IRS, ChargePoint, News, Lead, Pharmaceutical industry

The action charges ChargePoint with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points:

The action charges ChargePoint with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
As a result of ChargePoint’s materially misleading statements and omissions to the public, ChargePoint’s investors have suffered significant losses.
Kessler Topaz Meltzer & Check, LLP encourages ChargePoint investors who have suffered significant losses to contact the firm directly to acquire more information.
The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

Important March 5, 2024 ASRT Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Assertio Holdings, Inc. (ASRT) Investors of Securities Fraud Class Action Lawsuit

Retrieved on:

Monday, January 22, 2024

LLP, Person, Medicare, Adjustment, CFTC, Fraud, District court, Court, COPY, Acquisition, EPS, Suppository, FDA, IRS, News, Q3, Lead

The action charges Assertio with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points:

The action charges Assertio with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
As a result of Assertio’ s materially misleading statements and omissions to the public, Assertio’ s investors have suffered significant losses.
Kessler Topaz Meltzer & Check, LLP encourages Assertio investors who have suffered significant losses to contact the firm directly to acquire more information.
The class action complaint against Assertio, Shapiro v. Assertio Holdings, Inc., et al., Case No.

FINAL DEADLINE REMINDER FOR MDRX INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against Veradigm Inc. (MDRX)

Retrieved on:

Monday, January 22, 2024

LLP, Accounting, CFO, Insurance, Class, District court, MDRX, Court, COPY, Annual report, Nature, News, Lead, Pharmaceutical industry

The action charges Veradigm with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points:

The action charges Veradigm with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
Kessler Topaz Meltzer & Check, LLP encourages Veradigm investors who have suffered significant losses to contact the firm directly to acquire more information.
The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against BioNTech SE (BNTX)

Retrieved on:

Saturday, January 20, 2024

RADNOR, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).

Key Points:

RADNOR, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).
The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
As a result of BioNTech’ s materially misleading statements and omissions to the public, BioNTech’ s investors have suffered significant losses.
Kessler Topaz Meltzer & Check, LLP encourages BioNTech investors who have suffered significant losses to contact the firm directly to acquire more information.

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Mobileye Global Inc. (MBLY)

Retrieved on:

Friday, January 19, 2024

LLP, SOC, Insurance, EyeQ, District court, Court, COPY, News, Lead

RADNOR, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Mobileye Global Inc. (“Mobileye”) ( NASDAQ: MBLY ).

Key Points:

RADNOR, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Mobileye Global Inc. (“Mobileye”) ( NASDAQ: MBLY ).
The action charges Mobileye with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
Kessler Topaz Meltzer & Check, LLP encourages Mobileye investors who have suffered significant losses to contact the firm directly to acquire more information.
The class action complaint against Mobileye, Mcauliffe v. Mobileye Global Inc., et al., Case No.